BCL2 and neoplasm: Svensson et al. demonstrated that both caspase and Bcl-2 family mRNAs appeared in both sensitive and resistant cells before and after treatment with HAMLET complex using RNA protection techniques.78 Their findings exhibited a change in the profile of Bcl-2 family mRNA between tumor cells and normal cells with different sensitivities to treatment, but no variance in the responses to HAMLET treatment between the two cell types with the regulation of Bcl-2 marker in HAMLET-exposed cells.80 A related method was used to determine the specificity of mRNAs for various caspases.